The French National Authority for Health (Haute Autorité de santé) requested a registry study to obtain post-market surveillance data to describe baseline clinical profiles, management and outcome of patients treated with Zimino®. This study is designed to provide real-life data on the use, safety and clinical outcomes of Zimino® in routine clinical practice in France.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Indication for levosimendan (Zimino)
Timeframe: from January 28, 2020 until January 28, 2021
Dose of levosimendan (Zimino) (in µg/kg/min)
Timeframe: from January 28, 2020 until January 28, 2021
Duration of levosimendan (Zimino) infusion
Timeframe: from January 28, 2020 until January 28, 2021